Healthy human volunteers
Conditions
Interventions
The subject who assigned sequence 1 will receive CELECOXIB T.O. in period 1 then CELEBREXTM in period 2 separated with a washout period of 7 days. ,The subject who assigned sequence 2 will receive CEL
Experimental Drug,Active Comparator Drug
CELECOXIB T.O.,CELEBREXTM
Sponsors
T.O. Chemicals (1979) Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. Thai Male/Female must be 18-55 years of age, body mass index (BMI) = 18.0-25.0 kg/m2, inclusive. 2. Must be in good health as determined by medical history, vital signs (blood pressure (systolic blood pressure not lower than 90 or not over 129 mmHg, diastolic blood pressure not lower than 60 or not over 79 mmHg), body temperature, pulse rate, respiratory rate) and physical examination or showing no clinically significant abnormalities in the opinion of principal investigator or designated physicians 3. Screening electrocardiography (ECG) without clinically significant abnormalities 4. Screening visit laboratory values of blood test including hematology (complete blood count (CBC) with differential), fasting blood sugar (FBS), blood urea nitrogen (BUN), creatinine (Cr) and liver function test (aspartate aminotransferase (AST)/alanine aminotransferase (ALT), total bilirubin and alkaline phosphatase (ALP)) must be within the normal range or showing no clinically significant abnormalities in the opinion of principal investigator or designated physicians. 5. Thai CV risk score must be according to 2016 RCPT Clinical Practice Guideline on Pharmacologic Therapy of Dyslipidemia for Atherosclerotic Cardiovascular Disease Prevention or showing no clinically significant abnormalities in the opinion of principal investigator or designated physicians. Screening visit laboratory values of lipid profile (total cholesterol, High-density lipoprotein cholesterol (HDL-C), and triglyceride (TG) will be obtained for Low-density lipoprotein cholesterol (LDL-C) and Thai CV risk score calculation. 6. Urinalysis results within normal limit or showing no clinically significant abnormalities in the opinion of principal investigator or designated physicians 7. Must have serum hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (anti-HCV) negative 8. Female subjects must have beta-subunit of human chorionic gonadotropin in serum (β-HCG) negative. 9. Female subject who is childbearing potential or male subject agree to use an acceptable birth control method from visit 1 to the follow-up visit. The acceptable birth control method is defined as a barrier method of contraception (including condoms, intrauterine device and diaphragm with spermicidal agent) or total abstinence from sexual intercourse from visit 1 to the follow-up visit. Hormonal contraceptives are not acceptable. 10. Female subject who is non-childbearing potential (hysterectomy, both ovaries removed, surgically sterilized or postmenopausal (for at least 12 consecutive months of amenorrhea)) 11. Female subjects must agree not to become pregnant for the entire participation period and must have a negative result for a urine pregnancy test performing prior to dosing at period 1 and period 2. 12. Non-smokers (never smoked or no smoking within the previous 1 year) 13. Refrain from using herbal medications, dietary supplements (e.g., St. John’s Wort, ginkgo biloba, garlic supplements), vitamins, grapefruit or grapefruit juice, or pomelo within 14 days before the first administration of study drug (Day 1). Subjects must agree to refrain from these items until the last collection time-point of period 2. 14. Subjects must have ended any medications at least 30 days prior to Day 1 and agree to continue their refraining through
Exclusion criteria
Exclusion criteria: 1. Known hypersensitivity to celecoxib, sulfonamide, aspirin, or other NSAIDs, including other COX-2 specific inhibitors or any other similar class of drugs or its components 2. Past medical history of renal and hepatic insufficiency 3. Subject has a history of any illness that, in the opinion of principal investigator or designated physicians, might confound the result of the study or pose an additional risk in administering study drug to the subject. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular, gastrointestinal, central nervous system disease, renal and hepatic impairment; history or presence of clinically significant illness; or history of mental illness that may affect compliance with study requirements. 4. Have history of drug abuse (in the opinion of principal investigator or designated physicians, as judged by medical history) in the last 12 months 5. Have positive result of urine drug abuse testing on opioids (morphine (Mor), methadone (MTD)), cannabinoids (tetrahydrocannabinol (THC)), methamphetamine (Meth), cocaine (Coc) and methylenedioxy-methamphetamine (MDMA) at screening visit or before dose administration at each period 6. Alcohol abuse or excessive use (in the opinion of principal investigator or designated physicians, as judged by medical history) in the last 12 months 7. Have positive result of alcohol breathing test at screening visit or before dose administration at each period 8. Female subject is pregnant or breast feeding. 9. Difficulties fasting or consuming standard meals 10. Difficulties swallowing whole capsules 11. Donation or loss of whole blood: a. ≥50 mL and ≤499 mL within 30 days prior to dosing b. ≥500 mL within 56 days prior to dosing. 12. Participation in any investigational drug study within 1 month from screening visit (from the last follow-up visit to the screening visit)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cmax, AUC0-t, AUC0-inf Up to 48 hours post-administration PK parameters will be obtained from celecoxib plasma level using noncompartmental analysis | — |
Secondary
| Measure | Time frame |
|---|---|
| N/A N/A N/A | — |
Countries
Thailand
Contacts
Public ContactAssist. Prof. Pinpilai Jutasompakorn
Unaffiliated
Outcome results
None listed